BioCryst Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 78   

Articles published

BCRX 3.08 +0.10 (3.36%)
price chart
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Current Analyst Ratings
02/09/2016 - BioCryst Pharmaceuticals, Inc. was downgraded to “neutral” by analysts at JP Morgan. They now have a USD 5 price target on the stock.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Fundamental Star Rating Report
This is a fundamental star rating report for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) . The Capital Market Laboratories Star Rating is an objective, quantifiable measure of a company's operating and financial condition.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Annual EBIT At $-39.444 Millions  Enterprise Leader
Stock Up Nicely This Week: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Investors BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) are heading into the weekend on a positive note as the stock provided some gains this week moving 4.05% over the past 5 trading days.
BioCryst Pharmaceuticals Inc. (BCRX) Drops 5.21% on July 13
BioCryst Pharmaceuticals Inc. (BCRX) was one of the Russell 2000's biggest losers for Wednesday July 13 as the stock slid 5.21% to $2.91, a loss of $-0.16 per share.
HC Wainwright Maintains Buy On BioCryst Pharmaceuticals, Inc. (BCRX) Following ...
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares slipped yesterday 9% after the drug discovery company reported first-quarter results and update on its clinical progress.
New Roundup- Medivation (NASDAQ:MDVN), St. Jude Medical (NYSE:STJ), BioCryst ...  Seneca Globe
Stock Update (NASDAQ:BCRX): BioCryst Pharmaceuticals, Inc. Announces Clinical ...
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced results from OPuS-2 (Oral ProphylaxiS-2), a clinical trial of avoralstat administered three times daily as a liquid-filled soft gel formulation for the prophylactic treatment of hereditary ...
Is BioCryst Reaching Crush Depth?  24/7 Wall St.
BioCryst Pharmaceuticals, Inc Crashes on Failure of OPuS 2 Clinical Trial ...  Bidness ETC
BioCryst Pharmaceuticals, Inc. versus Eagle Pharmaceuticals Inc. Head to Head ...
Eagle Pharmaceuticals Inc. has a higher fundamental rating then BioCryst Pharmaceuticals, Inc. which has an impact on the head-to-head comparison.
BioCryst Pharmaceuticals Inc. (BCRX) Earns "Buy" Rating from FBR ...  Community Financial News
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Median Sales Estimate At $4.974  Equities Focus
Here's Why Shares of BioCryst Pharmaceuticals, Inc. Are Falling Today
What: Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX), a biotech company that specializes in the development of small molecular drugs, sank by over 20% today on heavy volume.
BioCryst Pharmaceuticals (BCRX) Stock Drops Despite Positive Drug Trial Results  TheStreet.com
BioCryst Announces Successful Phase 1 Clinical Trial of BCX7353  GlobeNewswire (press release)
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Is In The Spotlight
With regards to BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), most sell-side analysts seem to maintain a positive view on the stock.
Zacks EPS Estimates For BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
Zacks' mean and median EPS estimates for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) as of2016-12-31 are $-0.24 and $-0.23, respectively.